International Journal of Research in Pharmaceutical Sciences and Technology <p align="justify">Rubatosis Publication has launched its first online peer review scientific journal named International Journal of Research in Pharmaceutical Sciences and Technology (<strong>IJRPST, ISSN Online: 2581-9143</strong>). IJRPST will be published quarterly per year in January, April, July, and October. The journal publishes original research work that contributes significantly to further the scientific knowledge in Pharmaceutical Sciences and Technology.</p> Rubatosis Publications en-US International Journal of Research in Pharmaceutical Sciences and Technology 2581-9143 A comprehensive overview on nanofiber technology and their advancements in the field of pharmaceuticals <p>Nanotechnology is a growing technology that has been marked as the most vital scientific and commercial venture across the world with great benefits. Globally many researchers are involved in the development of newer types of nanomaterials through modifications of various fabrication techniques. Nanofibers have been an emerging trend in the field of nanomaterials due to its unique physicochemical characteristics. Properties such as high surface area and high porosity absorbance ratio with the interconnected fibrous networks makes nanofibers unique. The current review explores the present status and upcoming advancements in the field of nanofiber technology. The article is focused on the various preparation techniques and applications in medicine, tissue engineering and regenerative medicine and pharmaceuticals. Despite the advancements, the limitations and future prospects in the area of nanofiber technology have been highlighted.</p> N. Yamini SK. Arifa Begum Copyright (c) 2020 N. Yamini, SK. Arifa Begum 2020-11-02 2020-11-02 2 2 51 58 10.33974/ijrpst.v2i2.249 Simultaneous determination of levocetrizine and phenylpropanolamine hydrocholride by RP-HPLC <p>The aim of the present study was to develop the simple, selective, rapid, precise and economical reverse phase-high performance liquid chromatography (RP-HPLC) method for the simultaneous estimation of levocetirizine and phenylpropanolamine HCl in solid dosage forms. The method was carried out on a Phenomenex Luna C18 (25 cm × 4.6 mm i.d., 5 μ) column with a mobile phase consisting of acetonitrile: 0.5% triethylamine (70:30 v/v, pH 3.0) at a flow rate of 1.2 mL/min. Detection was carried out at 220 nm. The retention time (RT) 1.8 min and 2.6 min for phenylpropanolamine hydrocholride and levocetrizine respectively. The % recovery of standard phenylpropanolamine hydrocholride and levocetrizine was found to be 98.17 to 103.56 and 98.893 to 10.422 respectively. The % recovery of sample phenylpropanolamine hydrocholride and levocetrizine was found to be 101.30 and 100.63 respectively. The validation of the proposed method was also carried out. The proposed method can be used for the estimation of these drugs in combined dosage forms.</p> A. Srinivasan P. Divakar A. Maheswaran D. Saravanan Copyright (c) 2020 A. Srinivasan, P. Divakar, A. Maheswaran, D. Saravanan 2020-10-17 2020-10-17 2 2 32 36 10.33974/ijrpst.v2i2.238 Assessment of In-Vitro Cytotoxicity and In-Vivo Antitumor Activity of Syzygium aqueum <p>The present study aims to evaluate the cytotoxicity and antitumor activity of the ethanolic extract of<br>leaves of&nbsp;Syzygium aqueum&nbsp;(EESA) on K562 tumor cell line (chronic myeloid leukemia) and<br>transplantable tumor Dalton’s ascites lymphoma (DAL). In-vitro&nbsp;cytotoxicity on K562 tumor cell line<br>was evaluated using micro-culture tetrazolium (MTT) assay.&nbsp;In-vivo&nbsp;antitumor activity was studied on<br>DAL tumor bearing mice. Activity was assessed by monitoring the mean survival time, tumor cell<br>count, percentage increase in body weight and effect on haematological parameters like red blood cell<br>(RBC) count, haemoglobin content (Hb), white blood cell (WBC) count, Differential cell (DC) count.<br>Histopathological studies were also evaluated during this study. EESA exhibit potent&nbsp;in-<br>vitro&nbsp;cytotoxicity activity against K562 tumor cell line. The result also showed an increased life span<br>and decreased tumor cell count in&nbsp;S.aqueum&nbsp;treated animals. The hematological studies revealed that<br>the Hb count decreased in DAL bearing mice, whereas&nbsp;S.aqueum&nbsp;treated mice showed an increase in<br>the Hb or near to normal levels and other hematological parameters such as RBC, WBC was also<br>significantly reduced. Histopathalogical studies evaluated the destruction of tumor cells by showing<br>cell wall destruction, membrane blebbing, degradation, vacuolated cytoplasm. The results suggested<br>that the EESA exhibited cytotoxicity in dose dependent and it showed significant antitumor activity<br>on DAL bearing mice.</p> Irisappan Sarathchandrian P.Monisha Kavimani S Selvasudha N Copyright (c) 2020 Irisappan Sarathchandrian, P.Monisha, Kavimani S, Selvasudha N 2020-10-30 2020-10-30 2 2 37 43 10.33974/ijrpst.v2i2.246 Formulation and in-vitro characterization of erythromycin ocular inserts <p>Erythromycin has antibacterial activity and especially useful in the treatment of superficial infections involving conjunctivitis and/or cornea caused by organisms. Sustained drug therapies have more advantages than conventional. In the present study, an attempt was made to formulate sustained drug delivery system for Erythromycin in matrix type the formulations for Erythromycin containing 10%, 12%, and 14% w/v of Gelatin &amp; Hydroxy propyl methylcellulose, and 14% , 16%, and 18% w/v for Ethyl cellulose were prepared by solvent casting method and evaluated for their average weight variation, thickness, drug content, <em>in-vitro </em>drug release and stability studies. An increase in average weight and thickness is due to an increase in polymer concentration. IR spectral studies were performed to confirm the interaction of drug with excipients. IR spectrum revealed that there is no incompatibility and no drug-polymer interactions. <em>In vitro </em>drug release studies were performed by vial method. Gelatin F09, HPMC F15 and EC F21 exhibited maximum average weight 16.66 ± 0.02, 10.81 ± 0.01 &amp; 21.40 ± 0.01 mg respectively and thickness of 0.29 ± 0.01, 0.33± 0.06 and 0.43± 0.02mm respectively. The drug content was found to be 94.48, 92.87 &amp; 90.26% respectively. The <em>in-vitro </em>drug release studies showed that increase in polymer content decreases the drug release from ocular inserts. Formulations containing 16 % and 18% w/v of EC showed sustained and almost complete drug release and dissolved 86.99% and 85.00 % over 14hours period was selected as an ideal formulation. The dissolution data of above formulation were subjected to first order, Higuchi’s and peppa’s equations. The linearity and slope indicates that the release of erythromycin from the films might have followed Peppa’s double log plot and non Fickian characteristics. Drug release from the ocular insert by diffusion controlled mechanism. Stability studies conducted for F20 formulation. The formulation showed satisfactory physical stability at 25<sup>o</sup>C and 40<sup>o</sup>C at 60% and 75% RH respectively. The physical appearance had not changed considerably. It can be concluded that formulation containing EC 18 % w/v has achieved the objectives of increased contact time, prolonged release, decreased frequency of administration and thus may improve the patient compliance.</p> Shaik Harun Rasheed M. Samanvitha S.Y. Manjunath Copyright (c) 2020 M. Samanvitha, Shaik Harun Rasheed, S.Y. Majunath 2020-11-05 2020-11-05 2 2 44 50 10.33974/ijrpst.v2i2.245 Design, development and in-vitro evaluation of pinaverium colon targeted tablets <p>In the present research work colon formulation of Pinaverium targeted to colon by using various polymers developed. To achieve pH-independent drug release of Pinaverium, pH modifying agents (buffering agents) were used. Colon targeted tablets were preparedin two steps. Initially core tablets were prepared and then the tablets were coated by using different pH dependent polymers. Ethyl cellulose, Eudragit RLPO and S100 were used as enteric coating polymers. The precompression blend of all formulations was subjected to various flow property tests and all the formulations were passed the tests. The tablets were coated by using polymers and the coated tablets were subjected to various evaluation techniques. The tablets were passed all the tests. Among all the formulations F6 formulation was found to be optimized as it was retarded the drug release up to 18 hours and showed maximum of 98.45% drug release. It followed first order kinetics mechanism.</p> M. Neharika Shaik Harun Rasheed Copyright (c) 2020 M. Neharika , Shaik Harun Rasheed 2020-11-19 2020-11-19 2 2 59 66 10.33974/ijrpst.v2i3.244